Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab Phase 2b in Chronic Migraine
NCT02275117Phase 2Completed
- Sponsor
- Alder Biopharmaceuticals
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of eptinezumab in chronic migraine, sponsored by Alder Biopharmaceuticals. Started Oct 2014; status: completed.
02
Drugs
eptinezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT02275117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275117.